Results 181 to 190 of about 73,809 (216)

Global age-related seroprevalence for adeno-associated virus serotype 9 immunoglobulin G. [PDF]

Mol Ther Adv
Lo Bianco C, Chen CW, Jeeninga RE, Vietsch EE, van Olden RW.   +4 more
europepmc   +1 more source

Cell and Gene Therapies Manufacturing Challenges and Integrated Good Manufacturing Practices Solutions: A Lifecycle Perspective

Biotechnology and Bioengineering, EarlyView.
Lifecycle perspective on cell and gene therapy manufacturing challenges and enabling GMP solutions. ABSTRACT Cell and gene therapies (CGTs) are revolutionizing modern medicine; however, making these advanced medicines scalable and readily available to commercial manufacturers worldwide is a major challenge. The number of approved CGT products continues
Rajath Samaga, Udisha Singh, Sachin Dattram Pawar   +2 more
wiley   +1 more source

Identification of Recombinant Adeno-Associated Virus Serotypes by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry. [PDF]

Anal Chem
Nakatsuka R, Matsumoto K, Liu Y, Takeda K, Tsunaka Y, Torisu T, Yamaguchi Y, Uchiyama S.   +7 more
europepmc   +1 more source

Purification and concentration of model viruses using single‐pass tangential flow filtration

Biotechnology Progress, EarlyView.
Single‐pass TFF was developed for an enveloped and non‐enveloped virus for use in continuous downstream purification processes. Enveloped virus was concentrated and purified. Abstract The vaccine and viral vector industry is growing at an accelerated rate.
Luis Alberto Mejía‐Manzano, Lynn Manchester, Grace Wallis, Kan Wang, Bruce P. Lee, Michael Betenbaugh, Caryn L. Heldt   +6 more
wiley   +1 more source

Quantitative Analysis and Predictive Modeling of Nonspecific Adsorption of Recombinant Adeno-Associated Virus onto Solid Surfaces. [PDF]

Langmuir
Ueda Y, Shibuya R, Shibata K, Murai A, Tsunaka Y, Fukuhara M, Uchiyama S.   +6 more
europepmc   +1 more source

Status and future of recombinant adeno‐associated virus vector manufacturing

Biotechnology Progress, EarlyView.
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley   +1 more source

Pervasive horizontal transfer of adeno-associated virus capsid genes. [PDF]

Proc Natl Acad Sci U S A
Gifford RJ.
europepmc   +1 more source

Demonstration of nanofiltration‐based virus safety for AAV manufacturing using model viruses

Biotechnology Progress, EarlyView.
Abstract Virus safety for biopharmaceutical products has been a well‐established concern for several decades. While various virus reduction steps have been identified and implemented for traditional plasma‐derived and monoclonal antibody products, there are various challenges to achieving the same virus safety in emerging gene therapy products.
Brian Buesing, Tomoki Igi, Daniel Strauss   +2 more
wiley   +1 more source

A self-complementary recombinant adeno-associated virus vector coding for an anchorless prion protein carrying the G127V mutation extends survival in a rodent prion disease model. [PDF]

PLoS Pathog
Zerbes T, Verkuyl C, Zhang C, Grunnesjoe S, Eid S, Arshad H, Zhao W, Nasser Z, O'Shea T, Bel A, Lamoureux L, Frost KL, Myskiw J, Li LY, Stuart E, Wille H, Booth S, Watts JC, Schmitt-Ulms G.   +18 more
europepmc   +1 more source